Better Obesity Drug Race: Novo Nordisk vs Lilly 2026
In the race to dominate obesity drugs, Novo Nordisk and Eli Lilly are frontrunners. This guide analyzes who has the e...
Timing matters: choose or avoid depending on goals, fees, and flexibility. This guide offers practical criteria to decide for retirement planning.
21,768 articlesIn the race to dominate obesity drugs, Novo Nordisk and Eli Lilly are frontrunners. This guide analyzes who has the e...
Palantir sits at a crossroads of defense data and biotech action. This article explores why palantir's bold biosecuri...
Rumors are swirling about meta platforms reportedly getting into prediction markets. This potential pivot could redef...
Pi Network rolls out new ecosystem tools to broaden utility, while PI token drifts lower in a cautious crypto market....
A major reinsurance renewal helped Lemonade rewrite its profit picture, sending LMND higher in a short week. Here’s w...
Meta Platforms is nudging into cloud computing, aiming to monetize idle compute and AI-ready infrastructure. This art...
Salesforce leans on a sweeping buyback to defend its core, while ServiceNow expands through acquisitions focused on s...
A veteran Jefferies strategist outlines a split AI spend cycle: upfront hardware capex drives early gains, while long...
As American Express prepares to report earnings, the key question is how its card-fee growth stacks up against spendi...
A fresh recall of magsafe battery chargers recalled details new fire hazards linked to lithium-ion cells, with refund...
XRP remains in a tight battle between support and supply as July markets unfold. A breach of key levels could set XR...
Markets remain volatile in 2026, pushing investors toward durable, dividend-rich names. This report lays out the best...